INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
Feb 11, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 189,463 | $9.49 | 1,257,806 |
Feb 11, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 5,720 | $314.31 | 1,252,086 |
May 06, 2013 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 93,644 | $260.44 | 1,206,395 |
May 07, 2013 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 13,457 | $261.66 | 1,192,938 |
Feb 11, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 94,756 | $314.31 | 1,157,330 |
Feb 12, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 4,322 | $317.82 | 1,153,008 |
May 07, 2013 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 47,876 | $262.43 | 1,145,062 |
Feb 12, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 15,816 | $318.52 | 1,137,192 |
Dec 19, 2012 |
Director, EVP CSO Pres Regen Res Labs
|
Director, EVP CSO Pres Regen Res Labs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 7,692 | $13.00 | 1,117,330 |
Dec 12, 2013 |
Director, Pres Regeneron Labs
|
Director, Pres Regeneron Labs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 9,599 | $260.44 | 1,115,994 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.